In colon cancer, 4.5% (4/88) showed all three HER2 assays as positive; in NSCLC, 1.6% (1/64); in hepatobiliary, 10% (2/20); in bladder, 21% (4/19); and in rectal, 14.3% (2/14; Table 1). This evidence concerns the gene ERBB2 and malignant colon neoplasm.